To hear about similar clinical trials, please enter your email below
Trial Title:
Frequency and Risk Factors of Acute Myeloid Leukemia
NCT ID:
NCT05787951
Condition:
Myeloid Leukemia
Conditions: Official terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Bone marrow aspirite for diagnosis
Description:
Routine investigation of acute myeloid leukemia such as bone marrow aspirite for
diagnosis ,cbc
Summary:
1. to assess the frequency of acute myeloid leukemia at clinical Haematology unit of
Assiute university hospital
2. to study correlations of known risk factors and if there are new risk factors
participate in increasing frequency of acute myeloid leukemia
Detailed description:
Acute myeloid leukaemia (AML) is a rare heterogeneous disease comprising a group of
hematopoietic neoplasms originating from the excessive clonal proliferation of myeloid
pre- cursor cells [1]. Diagnosis of AML is based on morphological diagnosis with
proliferation of blast cells ≥ 20% of bone marrow cells, flow cytometric analysis and
cytogenetic abnormalities, including the t(8;21)(q22;q22), t(15;17) (q22;q12) and inv
(16)(p13.1;q22) which are associated with longer remission and survival, while
alterations of chromosomes 5, 7, complex karyotype and 11q23 are associated with poor
response to therapy and shorter overall survival [2] The etiological agent and
pathogenesis of AML are not entirely clear, only few AML cases can be accurately
classified through traditional cellular morphological classification [3]It is the most
common acute leukaemia in adults. It accounts for 1.3% of new cancer patients in the
United States, in 2018[ 4] Some factors are well documented to increase the risk of some
types of leukemia such as benzene exposure and ionizing radiation [5] increased frequency
of acute myeloid leukemia has been noticed at Haematology unit so the aim of the study to
assess the the frequency of acute myeloid leukemia and to evaluate the risk factors for
it .
Criteria for eligibility:
Study pop:
Adult Patients(above 18 years) diagnosed as acute myeloid leukemia according to WHO
diagnostic criteria
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Adult Patients(above 18 years) diagnosed as acute myeloid leukemia according to WHO
diagnostic criteria
Exclusion Criteria:
- Patients with other types of leukemia
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Healthy volunteers:
No
Start date:
May 1, 2023
Completion date:
August 1, 2025
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05787951
